132 related articles for article (PubMed ID: 34102541)
1. Polyclonal PAX8 expression in carcinomas of the biliary tract - Frequent non-specific staining represents a potential diagnostic pitfall.
Zong Y; Xiong Y; Dresser K; Yang M; Bledsoe JR
Ann Diagn Pathol; 2021 Aug; 53():151762. PubMed ID: 34102541
[TBL] [Abstract][Full Text] [Related]
2. Unexpected PAX8 Immunoreactivity in Metastatic High-grade Breast Cancer.
Kilgore MR; Bosch DE; Adamson KH; Swanson PE; Dintzis SM; Rendi MH
Appl Immunohistochem Mol Morphol; 2019 Oct; 27(9):637-643. PubMed ID: 30358609
[TBL] [Abstract][Full Text] [Related]
3. NY-BR-1 and PAX8 immunoreactivity in breast, gynecologic tract, and other CK7+ carcinomas: potential use for determining site of origin.
Woodard AH; Yu J; Dabbs DJ; Beriwal S; Florea AV; Elishaev E; Davison JM; Krasinskas AM; Bhargava R
Am J Clin Pathol; 2011 Sep; 136(3):428-35. PubMed ID: 21846919
[TBL] [Abstract][Full Text] [Related]
4. A comprehensive analysis of PAX8 expression in human epithelial tumors.
Laury AR; Perets R; Piao H; Krane JF; Barletta JA; French C; Chirieac LR; Lis R; Loda M; Hornick JL; Drapkin R; Hirsch MS
Am J Surg Pathol; 2011 Jun; 35(6):816-26. PubMed ID: 21552115
[TBL] [Abstract][Full Text] [Related]
5. PAX8 and PAX2 immunostaining facilitates the diagnosis of primary epithelial neoplasms of the male genital tract.
Tong GX; Memeo L; Colarossi C; Hamele-Bena D; Magi-Galluzzi C; Zhou M; Lagana SM; Harik L; Oliver-Krasinski JM; Mansukhani M; Falcone L; Hibshoosh H; O'Toole K
Am J Surg Pathol; 2011 Oct; 35(10):1473-83. PubMed ID: 21934480
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic utility of PAX8 and PAX2 immunohistochemistry in the identification of metastatic Müllerian carcinoma in effusions.
Wiseman W; Michael CW; Roh MH
Diagn Cytopathol; 2011 Sep; 39(9):651-6. PubMed ID: 20949455
[TBL] [Abstract][Full Text] [Related]
7. Pax8: a marker for carcinoma of Müllerian origin in serous effusions.
Tong GX; Devaraj K; Hamele-Bena D; Yu WM; Turk A; Chen X; Wright JD; Greenebaum E
Diagn Cytopathol; 2011 Aug; 39(8):567-74. PubMed ID: 20607683
[TBL] [Abstract][Full Text] [Related]
8. PAX8 (+)/p63 (-) immunostaining pattern in renal collecting duct carcinoma (CDC): a useful immunoprofile in the differential diagnosis of CDC versus urothelial carcinoma of upper urinary tract.
Albadine R; Schultz L; Illei P; Ertoy D; Hicks J; Sharma R; Epstein JI; Netto GJ
Am J Surg Pathol; 2010 Jul; 34(7):965-9. PubMed ID: 20463571
[TBL] [Abstract][Full Text] [Related]
9. Utility of monoclonal PAX8 antibody for distinguishing intrathyroid thymic carcinoma from follicular cell-derived thyroid carcinoma.
Suzuki A; Hirokawa M; Takada N; Higuchi M; Tanaka A; Hayashi T; Kuma S; Miyauchi A
Endocr J; 2018 Dec; 65(12):1171-1175. PubMed ID: 30210064
[TBL] [Abstract][Full Text] [Related]
10. PAX8 positivity in nested variant of urothelial carcinoma: a potential diagnostic pitfall.
Legesse T; Matoso A; Epstein JI
Hum Pathol; 2019 Dec; 94():11-15. PubMed ID: 31669177
[TBL] [Abstract][Full Text] [Related]
11. PAX8 Expression in Breast Cancer.
Lu S; Yakirevich E; Hart J; Wang L; Wang Y
Appl Immunohistochem Mol Morphol; 2021 Apr; 29(4):293-298. PubMed ID: 33208672
[TBL] [Abstract][Full Text] [Related]
12. PAX2 and PAX8: useful markers for metastatic effusions.
Waters L; Crumley S; Truong L; Mody D; Coffey D
Acta Cytol; 2014; 58(1):60-6. PubMed ID: 24334997
[TBL] [Abstract][Full Text] [Related]
13. PAX8 expression in anaplastic thyroid carcinoma is less than those reported in early studies: a multi-institutional study of 182 cases using the monoclonal antibody MRQ-50.
Lai WA; Hang JF; Liu CY; Bai Y; Liu Z; Gu H; Hong S; Pyo JY; Jung CK; Kakudo K; Bychkov A
Virchows Arch; 2020 Mar; 476(3):431-437. PubMed ID: 31732814
[TBL] [Abstract][Full Text] [Related]
14. Expression of CDX2 and Thyroid Transcription Factor-1 in Oropharyngeal Undifferentiated Carcinomas: A Potential Diagnostic Pitfall.
Chernock RD; Bibbey S; El-Mofty SK; Carpenter DH; Lewis JS
Appl Immunohistochem Mol Morphol; 2018 Apr; 26(4):268-273. PubMed ID: 27389559
[TBL] [Abstract][Full Text] [Related]
15. The role of GATA binding protein 3 in the differential diagnosis of collecting duct and upper tract urothelial carcinomas.
Gonzalez-Roibon N; Albadine R; Sharma R; Faraj SF; Illei PB; Argani P; Ertoy D; Allaf ME; Netto GJ
Hum Pathol; 2013 Dec; 44(12):2651-7. PubMed ID: 24071011
[TBL] [Abstract][Full Text] [Related]
16. Immunophenotypic and prognostic analysis of PAX8 and TTF-1 expressions in neuroendocrine carcinomas of thymic origin: A comparative study with their pulmonary counterparts.
Bi Y; Deng Y; Li S; Zhou X; Chen Y; Ma D; Mao X; Guan Y; Chen J; Meng Y
J Surg Oncol; 2016 Nov; 114(6):697-702. PubMed ID: 27761900
[TBL] [Abstract][Full Text] [Related]
17. Does Strong and Diffuse PAX-8 Positivity Occur in Primary Lung Carcinoma? An Immunohistochemical Study of 418 Cases and Review of the Literature.
McHugh KE; Arrossi AV; Farver CF; Mukhopadhyay S
Appl Immunohistochem Mol Morphol; 2019 Feb; 27(2):140-146. PubMed ID: 28777151
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of PAX8 Expression and Its Potential Diagnostic and Prognostic Value in Renal and Extra-Renal Ewing Sarcomas/PNETs.
Markow M; Bui MM; Lin HY; Lloyd M; Sexton WJ; Dhillon J
Pathol Oncol Res; 2016 Jan; 22(1):115-20. PubMed ID: 26350056
[TBL] [Abstract][Full Text] [Related]
19. Comparison of PAX8 Expression in Breast Carcinoma Using MRQ50 and BC12 Monoclonal Antibodies.
Singh K; Hanley LC; Sung CJ; Quddus MR
Appl Immunohistochem Mol Morphol; 2020 Aug; 28(7):558-561. PubMed ID: 31335489
[TBL] [Abstract][Full Text] [Related]
20. PAX8 reliably distinguishes ovarian serous tumors from malignant mesothelioma.
Laury AR; Hornick JL; Perets R; Krane JF; Corson J; Drapkin R; Hirsch MS
Am J Surg Pathol; 2010 May; 34(5):627-35. PubMed ID: 20414098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
